Guggenheim Lifts PT on Johnson & Johnson (JNJ) to $167 From $164, Keeps a Neutral Rating

Johnson & Johnson (NYSE:JNJ) is one of the top low volatility healthcare stocks to buy now. On July 17, Guggenheim raised the firm’s price target on Johnson & Johnson to $167 from $164, keeping a Neutral rating on the shares.

Johnson & Johnson (JNJ): I Counted 15 Separate Surprises," Says Jim Cramer

A smiling baby with an array of baby care products in the foreground.

The firm gave the price target upgrade after Johnson & Johnson delivered a “strong” Q2 and gave an “encouraging outlook” for its growth prospects in the second half of the year.

Guggenheim justified a Neutral rating on the stock by stating that it is waiting for increased visibility on the emerging Innovative Medicine pipeline that will need to offset Stelara’s decline.

Johnson & Johnson reported a 5.8% sales growth in Q2 2025 to $23.7 billion, with operational growth of 4.6% and adjusted operational growth of 3.0%. The company also raised its 2025 outlook, increasing full-year estimated reported sales guidance at the midpoint by $2 billion to 5.4% and full-year EPS guidance by $0.25 to $10.85.

This increase was supported by favorable foreign exchange results and strong operational performance by the company.

Johnson & Johnson develops, manufactures, and sells products in the healthcare field. The company operates through two segments: Innovative Medicine and MedTech.

The MedTech segment includes an elaborate range of medical devices and products used in cardiovascular intervention, orthopedics, interventional solutions, surgery, and vision fields.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

This article is originally published at Insider Monkey.